Drug General Information
Drug ID
D0S6KX
Former ID
DCL000827
Drug Name
GSK-677954
Drug Type
Small molecular drug
Indication Non-alcoholic fatty liver disease [ICD9: 571.8; ICD10:K76.0] Discontinued in Phase 2 [536649]
Company
GSK
Structure
Download
2D MOL

3D MOL

Formula
C34H36F3N3O4S2
Canonical SMILES
CCC(CC)(C(=O)O)OC1=CC=C(C=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3<br />)C(F)(F)F)N4CCN(CC4)C5=CC=C(C=C5)OC
InChI
1S/C34H36F3N3O4S2/c1-4-33(5-2,32(41)42)44-27-14-16-28(17-15-27)45-22-29-30(38-31(46-29)23-6-8-24(9-7-23)34(35,36)37)40-20-18-39(19-21-40)25-10-12-26(43-3)13-11-25/h6-17H,4-5,18-22H2,1-3H3,(H,41,42)
InChIKey
COHCTXOFKQXTRQ-UHFFFAOYSA-N
CAS Number
CAS 884324-15-6
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Peroxisome proliferator activated receptor gamma Target Info Agonist [536649]
Peroxisomeproliferator activated receptor delta Target Info Agonist [536649]
Peroxisome proliferator activated receptor alpha Target Info Agonist [536649]
KEGG Pathway PPAR signaling pathway
AMPK signaling pathway
Osteoclast differentiation
Huntington's disease
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancerhsa03320:PPAR signaling pathway
Wnt signaling pathway
Acute myeloid leukemiahsa03320:PPAR signaling pathway
cAMP signaling pathway
Adipocytokine signaling pathway
Glucagon signaling pathway
Non-alcoholic fatty liver disease (NAFLD)
Hepatitis C
NetPath Pathway IL1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Leptin Signaling PathwayNetPath_14:IL2 Signaling Pathway
PANTHER Pathway CCKR signaling map STP00057:Wnt signaling pathway
Pathway Interaction Database Noncanonical Wnt signaling pathway
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Signaling events mediated by HDAC Class I
RXR and RAR heterodimerization with other nuclear receptor
Regulation of retinoblastoma proteinps1pathway:Presenilin action in Notch and Wnt signaling
RXR and RAR heterodimerization with other nuclear receptorrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor
Reactome PPARA activates gene expression
Transcriptional regulation of white adipocyte differentiation
Nuclear Receptor transcription pathwayR-HSA-200425:Import of palmitoyl-CoA into the mitochondrial matrix
Regulation of pyruvate dehydrogenase (PDH) complex
Nuclear Receptor transcription pathwayR-HSA-1368082:RORA activates gene expression
BMAL1:CLOCK,NPAS2 activates circadian gene expression
YAP1- and WWTR1 (TAZ)-stimulated gene expression
Transcriptional activation of mitochondrial biogenesis
Activation of gene expression by SREBF (SREBP)
Nuclear Receptor transcription pathway
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Circadian Clock
WikiPathways Wnt Signaling Pathway Netpath
Nuclear Receptors in Lipid Metabolism and Toxicity
Differentiation of white and brown adipocyte
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
Transcriptional Regulation of White Adipocyte Differentiation
Adipogenesis
SREBP signalling
Nuclear ReceptorsWP399:Wnt Signaling Pathway and Pluripotency
NRF2 pathway
Nuclear Receptors Meta-Pathway
Vitamin D Receptor Pathway
Ectoderm Differentiation
Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity
Estrogen Receptor Pathway
PPAR Alpha Pathway
YAP1- and WWTR1 (TAZ)-stimulated gene expression
Activation of Gene Expression by SREBP (SREBF)
SREBF and miR33 in cholesterol and lipid homeostasis
Circadian Clock
Nuclear Receptors
References
Ref 536649Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.
Ref 536649Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.